Analysis of a large cohort of metastatic breast cancer samples shows that APOBEC mutational signatures are enriched in post-treatment samples. APOBEC activity was also associated with mutations known to drive drug resistance.
- Avantika Gupta
- Andrea Gazzo
- Sarat Chandarlapaty